Alkermes (ALKS +0.5%) says it's initiated Phase 3 clinical trials of ALKS 9070, its proprietary...

|About: Alkermes plc (ALKS)|By:, SA News Editor

Alkermes (ALKS +0.5%) says it's initiated Phase 3 clinical trials of ALKS 9070, its proprietary molecule designed to provide patients with a once-monthly dose for the treatment of schizophrenia. Results from the study, if positive, will be used to file a New Drug Application with the FDA.